The Transdisciplinary Centre for Biological Therapies is a multi-disciplinary, integrated approach to studying patients receiving therapies directed at the immune system. Our goal is to establish a real-world, prospective cohort of patients on biologics, immunotherapies, or other immunomodulating agents.
Translational studies are important ways to find new insights into the molecular basis of diseases including finding biomarkers that identify patients who will respond to their treatment ensuring that the right patient receives the right treatment at the right time. It is the cornerstone of precision medicine.
Resource for future research and development including identifying personalized biomarkers that will better predict patient outcomes. Being able to monitor the treatment efficacy of novel therapies, better manage adverse events, assist clinical decision-making, and optimize the cost benefits of immunotherapies, are some important benchmarks for advancing the standard of care.
Basic and Clinical Research including multi-disciplinary collaborative research initiatives, and working with the industry to foster cooperation and transfer of technology. Perform treatment validations using in-house laboratory platforms of immune regulations and interactions that can be applied to biospecimens obtained from consented patients enrolled in ongoing research and clinical studies.
Opal is a unique person-centered patient portal that was built and operated by the Opal Health Informatics Group at the RI-MUHC. Opal provides MUHC patients with access to some of their personal health information, such as appointment schedules and lab results. Opal also allows patients to answer questionnaires about their conditions and care and consent to sharing their health data for use in research
September 8th: CTTB Retreat
Place: TBD
11:00 AM – 6:00 PM
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
